Kyverna Therapeutics, Inc. (KYTX) AI Stock Analysis

• Market Cap: $114.53M
• Dividend Yield: N/A
• Average Volume (3M): 319.14K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.57
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: US
• Employees: 112
• Sector: General
• Sector Strength: N/A
• Industry: Biotechnology
• EPS (TTM): -1.03
• Shares Outstanding: 43,218,872
• 10 Day Avg. Volume: 465,144
• 30 Day Avg. Volume: 319,137
• PEG Ratio: 0.05
• Price to Book (P/B): 0.29
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -0.88
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $15.50
• Price Target Upside: 455.56% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 4

• Rating: 36 Underperform
• Price Target: ―

Kyverna Therapeutics, Inc. faces significant financial challenges, with consistent losses and zero revenue. The company's technical indicators and valuation metrics reflect ongoing operational and financial difficulties. Key risks include negative profitability and weak market momentum, which significantly impact the stock's performance.

Positive Factors

Clinical Trials

KYTX completed enrollment in the pivotal KYSA-8 trial for KYV-101 in SPS, with topline results and a BLA filing expected, opening the door to a first-to-market opportunity in an attractive rare-disease setting.

FDA Alignment

KYTX has gained alignment with FDA on their CMC package to support KYV-101 launch in SPS and other indications—important feedback and operational progress that should allow the company to efficiently support commercialization.

Financial Position

The stock trades at a significant discount to cash, with a market cap of $107M and cash of $243M, which is expected to provide a cash runway into 2027.

Negative Factors

Clinical Risks

Risks include lack of durable responses for patients treated with KYV-101 in LN or MG, failure to generate positive data for KYV-101 in SPS, and possible long-term dilution risk.

Financial Performance

Kyverna reported a net loss of $0.87 per share, vs. a prior estimate of a net loss of $0.70 per share.

Regulatory Environment

The broader development-stage biotech landscape has seen heightened regulatory risks stemming from the recent FDA shakeup.

Kyverna Therapeutics, Inc. Business Overview & Revenue Model

Company Description

Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial. The company is also developing KYV-201, an allogeneic CD19 CAR T-cell product candidate that is in preclinical stage to treat multiple autoimmune diseases. In addition, it is developing product candidates to treat other autoimmune diseases, such as inflammatory bowel disease that includes Crohn's disease and ulcerative colitis. Kyverna Therapeutics, Inc. has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product; and with Kite to research and develop programs for the treatment, diagnosis, and prevention of autoimmune, inflammatory, and allogeneic stem cell transplant inflammatory diseases. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.

How the Company Makes Money

Kyverna Therapeutics makes money primarily through the development and commercialization of its cell therapy products. The company may generate revenue through partnerships and collaborations with other biotech and pharmaceutical companies, which can include upfront payments, milestone payments, and royalties on sales of co-developed therapies. Additionally, Kyverna might engage in licensing agreements for its proprietary technologies, further contributing to its revenue streams. As a biotechnology firm, Kyverna may also secure funding from investors and grants to support its research and development efforts.

Kyverna Therapeutics, Inc. Financial Statement Overview

Summary

Kyverna Therapeutics, Inc. faces significant financial challenges, with zero revenue and consistent losses. The balance sheet is strong in equity but suffers from negative profitability. Cash flows are negative, though recent financing provides some liquidity.

Income Statement

Kyverna Therapeutics, Inc. shows significant challenges in generating revenue with total revenue at zero for the latest period. Net profit margins are negative, reflecting continuous losses over the years. EBIT and EBITDA margins are also negative, indicating operational inefficiencies. The revenue growth rate cannot be calculated due to zero revenue, highlighting the company's struggle in revenue generation.

Balance Sheet

The company has a strong equity base with a low debt-to-equity ratio due to significant stockholders' equity. However, the equity ratio is high, and the company is not highly leveraged, which is a positive sign. Return on equity is negative, reflecting the ongoing losses impacting shareholder returns. Overall, while the company maintains a relatively stable balance sheet, the profitability aspect is weak.

Cash Flow

Free cash flow is negative, indicating that the company is not generating enough cash to cover its capital expenditures. Operating cash flow is also negative, underscoring operational challenges. However, the company has managed significant financing cash inflows, which may provide some liquidity buffer. The ratio of operating cash flow to net income and free cash flow to net income is not favorable, showing cash flow difficulties.

Breakdown
TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement		Total Revenue
0.00	0.00	0.00	7.03M	5.66M
	Gross Profit
-1.47M	0.00	-1.71M	5.97M	5.07M
	EBIT
-122.94M	-142.60M	-62.41M	-29.38M	-26.35M
	EBITDA
-108.46M	-142.60M	-58.47M	-27.78M	-25.76M
	Net Income Common Stockholders
-110.66M	-127.48M	-60.37M	-28.89M	-26.35M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
51.32M	285.98M	57.54M	51.32M	76.07M
	Total Assets
66.92M	304.64M	75.19M	66.92M	85.49M
	Total Debt
10.56M	8.24M	9.08M	10.56M	5.55M
	Net Debt
-27.17M	-88.38M	-25.57M	-27.17M	-70.51M
	Total Liabilities
140.92M	38.06M	26.02M	140.92M	131.74M
	Stockholders Equity
-74.00M	266.59M	49.18M	-74.00M	-46.25M
Cash Flow		Free Cash Flow
-97.76M	-116.45M	-53.03M	-36.88M	-23.44M
	Operating Cash Flow
-95.75M	-114.25M	-52.41M	-36.11M	-22.16M
	Investing Cash Flow
-158.44M	-160.90M	-8.79M	-14.10M	-1.29M
	Financing Cash Flow
335.89M	337.11M	58.12M	11.88M	72.52M

Kyverna Therapeutics, Inc. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 2.79
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For KYTX, the sentiment is Positive. The current price of 2.79 is above the 20-day moving average (MA) of 2.33, above the 50-day MA of 2.18, and below the 200-day MA of 4.02, indicating a neutral trend. The MACD of 0.13 indicates Negative momentum. The RSI at 62.44 is Neutral, neither overbought nor oversold. The STOCH value of 79.09 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for KYTX.

Kyverna Therapeutics, Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	57 Neutral	$4.93B	19.97	-16.90%	5.27%	13.58%	-28.18%
ELUT	48 Neutral	$72.36M	―	149.62%	―	-18.22%	44.67%
ZNTL	46 Neutral	$92.10M	―	-59.45%	―	―	48.92%
CCCC	46 Neutral	$94.44M	―	-45.55%	―	98.56%	37.97%
CLYM	41 Neutral	$79.74M	―	-62.04%	―	―	-61.95%
KYTX	36 Underperform	$114.53M	―	-49.72%	―	―	―
VOR	33 Underperform	$29.28M	―	-125.43%	―	―	2.98%

Kyverna Therapeutics, Inc. Corporate Events

Kyverna Therapeutics Sets 2025 Strategic Priorities for Growth

Kyverna Therapeutics announces its strategic priorities for 2025, highlighting its focus on advancing the KYV-101 CD19 CAR T-cell therapy through late-stage development and commercialization for autoimmune diseases. The company aims to achieve a first-to-market position with KYV-101 for stiff person syndrome, with a BLA filing targeted for 2026, while also expanding its pipeline with KYV-102 to enhance CAR T accessibility. The company is focusing on capital-efficient growth and has a cash runway into 2027 to support its strategic goals.